Home
Sun Pharmaceutical Industries Limited
Press Release Mar 16 2026
Business
Mar 16 2026
3 min read

Press Release Mar 16 2026

Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated March 16, 2026, titled "Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis".

View Attachment